Editor-in-Chief
Full Professor Former Dean
Faculty of Medical Dentistry
Apollonia University of Iasi
Romania
Editor-in-Chief
Assistant Professor of Molecular Genetics and Biochemistry
Department of Molecular Genetics and Biochemistry
German International University
Egypt
Editor-in-Chief
Associate Professor Internal Medicine
DiMI Department of Internal Medicine
University of Genova
Italy
Editor-in-Chief
Professor
Faculty of Chemistry
California South University (CSU)
United States (USA)
Editor-in-Chief
Professor
Chemistry
King Fahd University of Petroleum & Minerals
Saudi Arabia
Editor-in-Chief
Assistant Professor
Pharmaceutical Analysis Research Center
Tabriz University of Medical Sciences
Iran
Editor-Member
Group Leader - Signal Transduction Unit
Department of Molecular Medicine and Surgery
Karolinska Institute
Sweden
Editor-Member
Department of Diagnostic and Therapeutic Technologies
Instituto Politécnico de Bragança
Portugal
Editor-Member
Faculty of Pharmacy
Faculty of Pharmacy, Minia University
King Khalid University
Egypt
Editor-Member
Associate Professor
Department of Pharmacy DIFAR
University of Genoa (UniGe), Italy
Italy
Editor-Member
Urmia University of Medical Sciences, Urmia, Iran
Iran
Editor-Member
Associate Professor
Faculty of Pharmacy
Odisha University of Health Sciences,Berhampur, Odisha
India
Editor-Member
Assistant Professor
Department of Chronic Diseases
Medical University of Silesia in Katowice
Poland
Editor-Member
Postgraduate Researcher
Department of Pharmaceutical Sciences
Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur
India
Editor-Member
PhD Researcher
Department of Analytical Chemistry
Faculty of Science, Tanta University
Egypt
Editor-Member
Professor
Faculty of Pharmacy
University of Medicine, Pharmacy, Science and Technology of Targu Mures
Romania
The Journal of Pharma and Drug Innovation (JPDI) is an international, peer-reviewed, open-access journal dedicated to advancing scientific knowledge and innovation in the pharmaceutical and drug development sciences. The journal serves as a dynamic platform for researchers, scientists, pharmacists, and healthcare professionals to share novel findings, explore emerging trends, and promote advancements that shape the future of pharma and drug innovation.
JPDI covers a comprehensive range of topics including pharmacology, pharmaceutics, pharmacognosy, medicinal chemistry, drug design and delivery, pharmaceutical biotechnology, regulatory sciences, toxicology, and clinical pharmacy. It emphasizes innovation-driven research and supports interdisciplinary collaboration that bridges the gap between laboratory discoveries and practical applications in healthcare.
The journal welcomes a wide variety of submissions, including original research articles, review papers, short communications, case reports, and opinion pieces that contribute to scientific advancement and enhance understanding in all aspects of drug discovery, development, and therapeutic optimization.
All manuscripts undergo a rigorous peer-review process to maintain the highest standards of scientific integrity, originality, and quality. Through its open-access policy, JPDI ensures that published research is freely accessible to readers worldwide, enhancing the global dissemination of knowledge and facilitating collaboration across disciplines and regions.
With a commitment to ethical publishing, academic excellence, and transparent editorial practices, the Journal of Pharma and Drug Innovation (JPDI) strives to become a leading international resource for pharmaceutical scientists, clinicians, and industry experts pursuing excellence in drug innovation and therapeutic advancement.
Submissions may be made through our online portal or by emailing manuscripts directly to the editorial office at editorialoffice@confseries.net
Authors are requested to submit manuscripts online at Submit Manuscript or Send as an e-mail attachment to the Editorial Office at editorialoffice@confseries.net
Rapid Publication Service
Confseries Publishing is offering wide range of opportunities, options and services for the prospective authors to publish their scholarly contributions.
The journal caters to the demands of the fast publication without compromising on the editorial quality including manuscript peer-review. This flexibility is being provided to ensure earliest author credibility to their respective contributions and this will also ensure timely dissemination of research outcomes for efficient integration, effective translation and reduced redundancy.
Authors have the option to choose between the standard open access publication service which takes its own course of time for complete publication process or can opt for rapid publication service wherein the article is published at the earliest date (Includes multiple subject experts commissioning for securing earliest peer-review comments). The authors can avail this flexibility based on the personal preference, funding agency guidelines or Institutional or organizational requirements.
Regardless of the option, all manuscripts undergo thorough peer-review process, editorial assessment and production process.
Fast Editorial Execution and Review Process (FEE-Review Process)
Authors who are willing to publish their articles under this mode can make a pre-payment of $99 towards express peer-review and editorial decision. First editorial decision in 3 days and final decision with review comments in 5 days from the date of submission. Galley proof generation will be done in next 2 days from acceptance or maximum 5 days (For manuscripts notified for revision by external reviewer).
Manuscripts accepted for publication will be charged regular APC.
Authors retain the copyright of their publication and the final version of the article will be published in both HTML and PDF formats as well as XML formats for transmitting to indexing databases. The editorial team of the Journal will ensure adherence to scientific publication guidelines.
Confseries follows a structured editorial and peer-review process designed to ensure academic quality, ethical integrity, and timely publication. Each manuscript progresses through clearly defined stages,as illustrated in the peer review workflow.
Manuscript Submission
Authors submit their manuscripts through the Confseries submission platform. All submissions must
comply with the journal’s scope, author instructions, and ethical standards.
Editorial Office Initial Check
Each new submission undergoes an initial assessment by the editorial office to confirm:
Manuscripts identified with major plagiarism, duplicate submission, or serious ethical issues are rejected at this stage without external review. Submissions meeting basic requirements proceed to peer review.
After passing the initial screening:
Reviewer Assessment
Reviewers critically evaluate the manuscript focusing on:
Editorial Decision
Based on reviewer feedback and editorial evaluation, one of the following decisions is issued:
Revision and Re-evaluation
For manuscripts requiring revision:
Acceptance and Publication
Manuscripts accepted for publication proceed to the production phase, which includes:
Ethical and Editorial Integrity
The Confseries peer-review workflow reflects a clear, ethical, and quality-driven editorial process, ensuring that every manuscript is evaluated rigorously before publication.
